Want to see HK:6826 full AI Analyst Report?
6826 Stock Chart & Stats
HK$24.90
-HK$0.40(-1.57%)
At close: 4:00 PM EST
HK$24.90
-HK$0.40(-1.57%)
Day’s Range― - ―
52-Week RangeHK$15.04 - HK$31.28
Previous CloseN/A
Volume220.22K
Average Volume (3M)211.55K
Market Cap
HK$7.73B
Enterprise ValueHK$2.89K
Total Cash (Recent Filing)HK$2.40B
Total Debt (Recent Filing)HK$416.01M
Price to Earnings (P/E)31.1
Beta0.89
Next Earnings
Aug 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield6.84%
Share Statistics
EPS (TTM)0.98
Shares Outstanding34,780,340
10 Day Avg. Volume238,704
30 Day Avg. Volume211,551
Financial Highlights & Ratios
PEG Ratio-0.51
Price to Book (P/B)0.94
Price to Sales (P/S)2.08
P/FCF Ratio11.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.6
Revenue Forecast (FY)HK$2.61B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low debt relative to equity gives the company durable financial flexibility: it can fund R&D, inventory and working-capital needs without material refinancing risk. This conservatism supports resilience through mid-term demand cycles and enables opportunistic investment over 2–6 months.
Diversified Product MixA multi-segment portfolio spanning ophthalmology, medical aesthetics and wound care reduces single-market dependency. Replenishable surgical consumables and repeat-purchase aesthetics products create recurring demand channels, supporting steadier revenue streams and channel resilience over the medium term.
Positive Operating And Free Cash FlowSustained positive operating cash flow and material free cash flow provide internal funding for capex, working capital and shareholder returns. Even with some decline, positive FCF underpins near-term self-funding capacity and reduces reliance on external financing for strategic initiatives.
Bears Say
Weakening Revenue And EBITRecent topline contraction and a sharp drop in operating profit signal deteriorating operational momentum. If demand or pricing pressure persists, the business may face prolonged margin headwinds and reduced capacity to invest, weakening medium-term earnings power and growth prospects.
Declining FCF And Moderate Cash ConversionA steep drop in free cash flow and cash conversion below parity mean reported earnings are not reliably turning into spendable cash. This reduces financial optionality for reinvestment or dividends and raises the risk that operating pressures will force tighter capital allocation or external funding.
Compressed Returns And EPS DeclineLow and falling ROE alongside sharply negative EPS growth indicate weakening profitability relative to equity. Persistently low returns constrain the company's ability to compound shareholder value and may reflect structural margin pressure or fading competitive advantages over the medium term.
Shanghai Haohai Biological Technology Co., Ltd. Class H News
6826 FAQ
What was Shanghai Haohai Biological Technology Co., Ltd. Class H’s price range in the past 12 months?
Shanghai Haohai Biological Technology Co., Ltd. Class H lowest stock price was HK$15.04 and its highest was HK$31.28 in the past 12 months.
What is Shanghai Haohai Biological Technology Co., Ltd. Class H’s market cap?
Shanghai Haohai Biological Technology Co., Ltd. Class H’s market cap is HK$7.73B.
When is Shanghai Haohai Biological Technology Co., Ltd. Class H’s upcoming earnings report date?
Shanghai Haohai Biological Technology Co., Ltd. Class H’s upcoming earnings report date is Aug 22, 2026 which is in 15 days.
How were Shanghai Haohai Biological Technology Co., Ltd. Class H’s earnings last quarter?
Shanghai Haohai Biological Technology Co., Ltd. Class H released its earnings results on Apr 24, 2026. The company reported HK$0.372 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Shanghai Haohai Biological Technology Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Haohai Biological Technology Co., Ltd. Class H’s price is currently Overvalued.
Does Shanghai Haohai Biological Technology Co., Ltd. Class H pay dividends?
Shanghai Haohai Biological Technology Co., Ltd. Class H pays a Quarterly dividend of HK$0.688 which represents an annual dividend yield of 6.84%. See more information on Shanghai Haohai Biological Technology Co., Ltd. Class H dividends here
What is Shanghai Haohai Biological Technology Co., Ltd. Class H’s EPS estimate?
Shanghai Haohai Biological Technology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Haohai Biological Technology Co., Ltd. Class H have?
Shanghai Haohai Biological Technology Co., Ltd. Class H has 34,780,340 shares outstanding.
What happened to Shanghai Haohai Biological Technology Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai Haohai Biological Technology Co., Ltd. Class H reported an EPS of HK$0.372 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.19%.
Which hedge fund is a major shareholder of Shanghai Haohai Biological Technology Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6826
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Haohai Biological Technology Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.53%
12-Months-Change
Fundamentals
Return on Equity
6.84%
Trailing 12-Months
Asset Growth
-1.06%
Trailing 12-Months
Company Description
Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. is a global enterprise dedicated to the research, development, manufacturing, and commercialization of biomedical materials. Its operations span Mainland China, the United States, the United Kingdom, and various other international regions. A comprehensive product portfolio addresses several key medical disciplines. Within ophthalmology, offerings include intraocular lenses, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, injectors, and surgical scalpels. Orthopedics products encompass sodium hyaluronate injections and medical chitosan. For wound repair, it manufactures recombinant human epidermal growth factor, effective in treating burn wounds, residual wounds, donor site post-traumatic wounds, and both fresh and chronic ulcerations. Additionally, the company develops anti-adhesion materials, including medical sodium hyaluronate gel and medical chitosan, as well as hemostatic solutions such as collagen sponges and porcine fibrin sealants. Beyond its therapeutic offerings, Shanghai Haohai maintains a significant presence in the medical aesthetics market. This segment features a range of hyaluronic acid (HA) dermal fillers: Matrifill, positioned as a first-generation mono-phase injectable HA gel; Janlane, a second-generation filler engineered for dynamic application; and Hyalumatrix, a third-generation product providing precise aesthetic embellishment. Its aesthetic portfolio is further complemented by radio frequency devices and laser equipment. Furthermore, the company actively engages in the research and development of biological engineering and pharmaceutical products, extending services such as technology transfer and consultation. It also conducts investment and trading operations. Established in 2007, the entity initially traded as Haohai Limited before officially adopting the name Shanghai Haohai Biological Technology Co., Ltd. in 2010. Its corporate headquarters are based in Shanghai, China.
Shanghai Haohai Biological Technology Co., Ltd. Class H (6826) Earnings & Revenues
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Pharmaron Beijing Co., Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―